Menu
Search
|

Menu

Close
X

Foundation Medicine Inc FMI.OQ (NASDAQ Stock Exchange Global Select Market)

76.60 USD
-- (--)
As of 2:29 AM IST
chart
Previous Close 76.60
Open --
Volume --
3m Avg Volume 81,707
Today’s High --
Today’s Low --
52 Week High 78.00
52 Week Low 22.40
Shares Outstanding (mil) 36.02
Market Capitalization (mil) 1,689.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.57 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
61
FY16
117
FY15
93
EPS (USD)
FY17
-2.552
FY16
-3.249
FY15
-2.721
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
14.13
5.77
Price to Book (MRQ)
vs sector
18.83
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-96.15
14.43
Return on Equity (TTM)
vs sector
-101.97
16.13

EXECUTIVE LEADERSHIP

Michael Pellini
Chairman of the Board, Since 2017
Salary: $511,808.00
Bonus: --
Troy Cox
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Jason Ryan
Chief Financial Officer, Principal Financial Officer, Principal Accounting officer, Since 2015
Salary: --
Bonus: --
Konstantin Fiedler
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Robert Hesslein
Senior Vice President, General Counsel, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

150 2nd St
CAMBRIDGE   MA   02141-2115

Phone: +1617.4182200

Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer. Its suite of clinical molecular information products includes FoundationOne, which is used for solid tumors; FoundationOne Heme, which is used for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma, pediatric cancers and advanced sarcoma; FoundationACT (Assay for Circulating Tumor DNA), which is a blood-based (liquid biopsy) assay that evaluates circulating tumor deoxyribonucleic acid (ctDNA), and FoundationFocus CDxBRCA, which is a companion diagnostic assay to aid in identifying women with ovarian cancer for whom treatment with Rubraca (rucaparib).

SPONSORED STORIES